INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
MHRA confirms that hospital pharmacies can manufacture, transport and store gene therapy products, and the Care Quality Commission will be responsible, not MHRA

MHRA confirms that hospital pharmacies can manufacture, transport and store gene therapy products, and the Care Quality Commission will be responsible, not MHRA

What!!! Yes, it's true, read all about it...

Hedley Rees's avatar
Hedley Rees
Jan 10, 2023
∙ Paid
47

Share this post

INSIDE PHARMA
INSIDE PHARMA
MHRA confirms that hospital pharmacies can manufacture, transport and store gene therapy products, and the Care Quality Commission will be responsible, not MHRA
23
Share

Delighted to report there has been a breakthrough with MHRA

This morning, I received this email from Ian Rees, Manager, Inspectorate Strategy and Innovation Unit”

“Dear Hedley

Many thanks, I had a good break.

Thank you for your reply and I can confirm that I have passed this information on to the Directorate.

To resolve this matter, we now need to have a call with you – please let me know what dates and time are suitable for you and I will send a Team invitation.

Regards

Ian”

This is the latest email exchange over my FOI request outlined below:

INSIDE PHARMA
MHRAs reply to Hedley's FOI request and open letter—it didn't say anything new...
MHRA replied on time Some of you may remember this Freedom of Information request I put in to MHRA on 14th November: FOI request and open letter to MHRA—please share far and wide... The reply came back yesterday and I replied today. It wasn’t very convincing…
Read more
3 years ago · 21 likes · 17 comments · Hedley Rees

This is the FOI request.

The email from Ian was in response to my email the day before, see below:

“Dear Ian,

Yes, the break was welcome, hope you enjoyed yours too.

The answer below is very helpful, albeit it does not address the majority of the questions posed [in the FOI]. In spite of that, it has allowed me to establish that any ATMP approved by MHRA under the changed regulations, has the potential to be misbranded. The logic is this. The application f…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share